[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. (NRSN) filed a Form 6-K detailing the outcome of its pre-New Drug Submission (pre-NDS) meeting with Health Canada concerning PrimeC, the company’s investigational therapy for amyotrophic lateral sclerosis (ALS). The regulator discussed use of the Notice of Compliance with Conditions (NOC/c) expedited pathway, which could shorten the review timeline if eligibility is granted.

The parties are finalizing official minutes; a formal notice will confirm whether NeuroSense can proceed with an NDS under the NOC/c route. Management described the dialogue as constructive and positive but disclosed no definitive decision, review timetable, or financial metrics.

A comprehensive forward-looking statements section highlights risks including potential rejection or delay by Health Canada, funding requirements, Phase 3 timing, market-size uncertainties, and the company’s ability to remain listed on Nasdaq. No earnings data or new operational figures were provided.

Positive

• Constructive pre-NDS meeting with Health Canada signals progress toward the NOC/c expedited approval pathway.
• Potential early market entry for PrimeC in Canada could accelerate commercialization if eligibility is granted.

Negative

• No formal eligibility confirmation yet; regulatory outcome remains uncertain.
• Extensive risk disclosures cite possible delays, funding needs, and market-size uncertainties.

Insights

Pharmaceutical Regulatory Specialist

TL;DR: Constructive Health Canada meeting moves PrimeC closer to fast-track filing; approval and timing still uncertain.

Health Canada’s openness to an NOC/c filing is a tangible step toward accelerated Canadian access to PrimeC, potentially cutting 6-12 months off a standard review. While encouraging, the company lacks formal eligibility confirmation; filing cannot begin until the notice is received. Investors should weigh the positive tone against sizable regulatory and financing risks disclosed.

Equity Research Analyst

TL;DR: Positive signal but no near-term revenue impact; valuation unchanged.

The update marginally improves PrimeC’s probability of approval, aiding the narrative ahead of Phase 3 planning. However, absent cash-flow data and an uncertain timeline, the filing does not materially alter near-term financial forecasts. The extensive risk language suggests potential dilution if further capital is required.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2025

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

NeuroSense Therapeutics Ltd. (the “Company”) reports that, following its prior public communications on the matter, the Company has completed its pre-New Drug Submission (pre-NDS) meeting with Health Canada regarding the potential early approval of PrimeC for the treatment of ALS, under the expedited Notice of Compliance with Conditions (NOC/c) pathway.

The Company and Health Canada are currently finalizing the official meeting minutes, after which the Company will receive formal notification regarding its eligibility to proceed with an NDS under the NOC/c pathway. The Company was highly encouraged by the constructive dialogue and positive tone of the meeting and looks forward to providing a comprehensive update following receipt of the official notification.

This Report on Form 6-K is hereby incorporated by reference into registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Forward-Looking Statements

This Form 6-K release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding a meeting with Health Canada. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the Health Canada will not approve PrimeC under the NOC/c pathway, or at all, or such approval will be delayed, that partnership discussions regarding PrimeC will not lead to execution of a definitive agreement, or that, if executed, will not lead to the current anticipated benefits to NeuroSense, a delay in the planned Phase 3 study for PrimeC in ALS or that its scope will be different than anticipated, lower than anticipated market opportunity in Canada and elsewhere, the risk that NeuroSense will need capital earlier than currently anticipated, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: June 26, 2025	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2

FAQ

What milestone did NeuroSense Therapeutics (NRSN) report?

The company completed a pre-NDS meeting with Health Canada for PrimeC under the expedited NOC/c pathway.

Is PrimeC now accepted for review by Health Canada?

Not yet. NeuroSense must receive formal notification confirming eligibility to file an NDS.

Why is the NOC/c pathway significant for NeuroSense?

It could provide accelerated approval, allowing conditional Canadian market entry while confirmatory studies continue.

Were any financial results disclosed in this 6-K?

No financial figures or earnings guidance were included.

What key risks were highlighted?

Risks include regulatory delays, funding requirements, Phase 3 changes, and market uncertainty.